MAM
AXSM icon

Martingale Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Martingale Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Sell
12,509
-3
-0% -$651 0.07% 292
2026
Q1 		$2.11M Buy
12,512
+5,106
+69% +$882K 0.05% 339
2025
Q4 		$1.35M Buy
7,406
+3,606
+95% +$503K 0.03% 406
2025
Q3 		$462K Sell
3,800
-1
-0% -$113 0.01% 625
2025
Q2 		$397K Buy
+3,801
New +$402K 0.01% 652

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Martingale Asset Management's AXSM Position: Q2 2026 in Review

Martingale Asset Management reduced its Axsome Therapeutics (AXSM) stake by 0.02% in Q2 2026, selling an estimated $651 and leaving 12,509 shares worth $3.06M. The position accounts for 0.07% of the portfolio, ranked #292.

Martingale Asset Management first reported a position in AXSM in Q2 2025 and has held it in 5 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Martingale Asset Management held 12,509 shares of Axsome Therapeutics worth $3.06M as of Q2 2026.
  • Martingale Asset Management sold 3 Axsome Therapeutics shares in Q2 2026, an estimated $651.
  • Axsome Therapeutics made up 0.07% of Martingale Asset Management's portfolio in Q2 2026, its #292 holding.
  • Martingale Asset Management first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.